Claims for Patent: 10,525,118

Summary for Patent: 10,525,118

Title:	Recombinant Mycobacterium as an immunotherapeutic agent for the treatment of cancer
Abstract:	The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
Inventor(s):	Grode; Leander (Braunschweig, DE)
Assignee:	Vakzine Projekt Management GmbH (Hannover, DE)
Application Number:	15/571,415
Patent Claims:	1. A method for the immunotherapy of bladder carcinoma in a human subject in need thereof, comprising administering to said subject a urease C-deficient recombinant Mycobacterium bovis Bacillus Calmette-Guerin (BCG) cell from strain Danish subtype Prague as an immunotherapeutic agent, comprising a recombinant nucleic acid molecule encoding a fusion polypeptide comprising: (a) a domain capable of eliciting an immune response, and (b) a Listeria phagolysosomal escape domain listeriolysin (Hly), wherein said immunotherapeutic agent is administered by vesicular instillation into said human subject's urinary bladder to produce focal and multifocal lymphocytic infiltration. 2. The method of claim 1, wherein the focal and/or multifocal lymphocytic tissue infiltration is increased compared to administration of native BCG. 3. The method of claim 1, wherein said immunotherapeutic agent is administered to patients with newly diagnosed or recurrent bladder carcinoma who have not been treated previously with standard BCG. 4. The method of claim 1, wherein said immunotherapeutic agent is administered to patients with recurrent bladder carcinoma who have been treated previously with standard BCG. 5. The method of claim 1, wherein the bladder carcinoma is selected from the group consisting of non-invasive bladder carcinoma, non-invasive papillary carcinoma (T.sub.a), and a tumor invading subepithelial connective tissue (T.sub.1). 6. The method of claim 5, wherein said non-invasive bladder carcinoma is carcinoma in situ (T.sub.cis). 7. The method of claim 1, wherein the immunotherapeutic agent is administered after surgery. 8. The method of claim 1, wherein the immunotherapeutic agent is administered into the human subject's urinary bladder according to a schedule involving weekly instillations during an induction phase, a first maintenance phase after about 3 months, a second maintenance phase after about 6 months and a third maintenance phase after about 12 months. 9. The method of claim 8, wherein the immunotherapeutic agent is administered into the bladder according to a schedule involving weekly instillations during an induction phase with 6 weekly instillations, a first maintenance phase after about 3 months with 3 weekly instillations, a second maintenance phase after about 6 months with 3 instillations and a third maintenance phase after about 12 months with 3 instillations. 10. The method of claim 1, wherein the immunotherapeutic agent is used at a dose of from about 10.sup.6 to 10.sup.10 CFU per administration. 11. The method of claim 1, wherein the immunotherapy further comprises a non-tumor site specific administration of the urease C-deficient recombinant Mycobacterium bovis Bacillus Calmette-Guerin (BCG) cell from strain Danish subtype Prague.

Details for Patent 10,525,118

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2035-05-04